Digital Meet the innovators doing precision health, medicine NOW At Frontiers Health 2023, a panel will look at paradigm-shifting precision health work in the cardio-metabolic space. Dr Charles Alessi tells us more.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.